Premium
Expression of both B7‐1 and CD28 contributes to the IL‐2 responsiveness of CTLL‐2 cells
Author(s) -
BELANI R.,
WEINER G. J.
Publication year - 1996
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1046/j.1365-2567.1996.461532.x
Subject(s) - cd28 , expression (computer science) , microbiology and biotechnology , biology , cancer research , immunology , t cell , immune system , computer science , programming language
The CTLL‐2 bioassay is used frequently to determine interleukin‐2 (IL‐2) concentrations in experimental samples, including samples that contain reagents which affect the CD28–B7 interaction. We therefore evaluated whether the CD28–B7 pathway plays a role in the growth of CTLL‐2 cells. Flow cytometry demonstrated that CTLL‐2 cells express both CD28 and B7‐1. CTLA4–immunoglobulin (CTLA4‐Ig) inhibited the growth of CTLL‐2 cells over a range of IL‐2 concentrations, suggesting that the CD28–B7 interaction plays an important role in the growth of CTLL‐2 cells. Anti‐B7‐1 antibody also inhibited CTLL‐2 proliferation at all concentrations of IL‐2. These results indicate that the CTLL‐2 bioassay may not be a reliable means of determining IL‐2 levels in experimental samples containing reagents that affect the CD28–B7 interaction. They also suggest that co‐expression of CD28 and B7 may contribute to the growth of malignant T cells.